Actuate Therapeutics (ACTU) Non Operating Income (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Non Operating Income of $134520.0 for Q4 2025, up 19.0% year-over-year from $113039.0 in Q4 2024, and up 107.25% quarter-over-quarter from $64908.0 in Q3 2025.
Actuate Therapeutics (ACTU) Non Operating Income (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Non Operating Income for 3 consecutive years, with $134520.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income rose 19.0% year-over-year to $134520.0; the TTM figure through Dec 2025 stood at $267460.0 (up 112.59% YoY), while the FY2025 annual figure was $267460.0, up 112.59% from the prior year.
- Non Operating Income climbed to $134520.0 in Q4 2025 per ACTU's latest filing, from $64908.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $137748.0 in Q3 2023 and bottomed at -$1.1 million in Q2 2024.
- Historically, Non Operating Income has averaged -$150566.0 across 3 years, with a median of $48560.0 in 2025.
- On a YoY basis, Non Operating Income climbed as much as 3634.36% in 2024 and fell as far as 1990.43% in 2024.
- Actuate Therapeutics' Non Operating Income stood at $3027.0 in 2023, then jumped by 3634.36% to $113039.0 in 2024, then climbed by 19.0% to $134520.0 in 2025.
- Business Quant data shows ACTU's Non Operating Income at $134520.0 in Q4 2025, $64908.0 in Q3 2025, and $19472.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | 39,953.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 134,520.00 |
| Sep 30, 2025 | 64,908.00 |
| Jun 30, 2025 | 19,472.00 |
| Mar 31, 2025 | 48,560.00 |
| Dec 31, 2024 | 113,039.00 |
| Sep 30, 2024 | -578,058.00 |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | -522,805.00 |
| Dec 31, 2023 | 3,027.00 |
| Sep 30, 2023 | 137,748.00 |
| Jun 30, 2023 | 60,133.00 |